Market AdoptionYorvi's US launch logged 1,750 start forms from approximately 1,000 unique prescribers, indicating rapid uptake and widespread adoption.
Product LaunchThe Yorvipath launch in HypoPTH is expected to be a significant driver for shares to top $200.
Revenue GrowthU.S. sales of 26M EUR were approximately double the expectations of 14M EUR, highlighting strong revenue performance.
Sales PerformanceYorvipath has shown strong sales numbers, exceeding consensus estimates by over 40% and even surpassing aggressive estimates.